{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:28:17Z","timestamp":1771334897602,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-05811-y","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T05:01:45Z","timestamp":1716872505000},"page":"5691-5701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4813-8618","authenticated-orcid":false,"given":"Giuseppe","family":"Mele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Derudas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Conticello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregorio","family":"Baril\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candida","family":"Germano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Reddiconto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Sgherza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"De Novellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlotta","family":"Galeone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Agavni\u2019","family":"Castiglioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Deiana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pascarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica Antonia","family":"Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Foggetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilenia","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Di Renzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Tarantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"issue":"3","key":"5811_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosinol","year":"2021","unstructured":"Rosinol L, Beksac M, Zamagni E et al (2021) Expert review on soft-tissue plasmacytoma in multiple myeloma: definition, disesase assessment and treatment consideration. Br J Haematol 194(3):496\u2013507","journal-title":"Br J Haematol"},{"issue":"3","key":"5811_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3)","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J and al (2022) Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 12(3):45. https:\/\/doi.org\/10.1038\/s41408-022-00643-3)","journal-title":"Blood Cancer J"},{"issue":"1","key":"5811_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3324\/haematol.2019.219295","volume":"105","author":"M Beksac","year":"2020","unstructured":"Beksac M, Seval GC, Kanellias N et al (2020) A real world multicenter retrospective study on extramedullary disease from balkan myeloma study group and Barcelona University: analysis of parameters that improve outcome. Haematologica 105(1):201\u2013208","journal-title":"Haematologica"},{"issue":"3","key":"5811_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E et al (2021) Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(3):309\u2013322","journal-title":"Ann Oncol"},{"key":"5811_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11899-019-00507-x","volume":"14","author":"M Offidani","year":"2019","unstructured":"Offidani M, Boccadoro M, Di Raimondo F et al (2019) Expert Panel Consensus Statement for proper evaluation of First Relapse in multiple myeloma. Curr Hematol Malig Rep 14:187\u2013196","journal-title":"Curr Hematol Malig Rep"},{"issue":"19","key":"5811_CR6","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1182\/blood.2020008733","volume":"139","author":"E Zamagni","year":"2022","unstructured":"Zamagni E, Barbato S, Cavo M (2022) How I treat high-risk multiple myeloma. Blood 139(19):2889\u20132903","journal-title":"Blood"},{"key":"5811_CR7","doi-asserted-by":"crossref","unstructured":"Moreau P, Mateos MV, Goldschmidt H et al (2023) Outcome of patients with extramedullay disease in triple-class exposed relapsed\/refractory multiple myeloma from the LocoMMotion\u2009+\u2009MoMMent studies. 65th ASH Annual Meeting & Exposition, n. 4698","DOI":"10.1182\/blood-2023-181235"},{"issue":"6","key":"5811_CR8","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/jcm8060877","volume":"8","author":"C Conticello","year":"2019","unstructured":"Conticello C, Romano A, De Fabro V et al (2019) Feasibility, tolerability and efficacy of carfilzomib in combination with lenalidomide and dexamethasone in relapsed refractory myeloma patients: a retrospective real-live survey of the Sicilian Myeloma Network. JCM 8(6):877","journal-title":"JCM"},{"issue":"1","key":"5811_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hon.2820","volume":"39","author":"S Rocchi","year":"2021","unstructured":"Rocchi S, Tacchetti P, Pantani L et al (2021) A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide and dexamethasone (KRD) in relapsed\/refractory multiple myeloma. Hemat Onc 39(1):41\u201350","journal-title":"Hemat Onc"},{"issue":"2","key":"5811_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00277-020-04329-3","volume":"100","author":"A Mele","year":"2021","unstructured":"Mele A, Prete E, De Risi C et al (2021) Carfilzomib, lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP). Ann Hemat 100(2):429\u2013436","journal-title":"Ann Hemat"},{"key":"5811_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/cancers12041035","volume":"12","author":"X Zhou","year":"2020","unstructured":"Zhou X, Fluchter P, Nickel K et al (2020) Carfilzomib based treatment strategies in the management of relapsed\/refractory multiple myeloma with extramedullary disease. Cancers 12:1035","journal-title":"Cancers"},{"issue":"13","key":"5811_CR12","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1080\/10428194.2020.1802452","volume":"61","author":"E Antonioli","year":"2020","unstructured":"Antonioli E, Staderini M, Pilerci S et al (2020) Daratumumab, lenalidomide, and dexamethasone combination in relapsed\/refractory myeloma patients: a real-life single-center experience. Leuk Lymphoma 61(13):3255\u20133258","journal-title":"Leuk Lymphoma"},{"key":"5811_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bjh.13799","volume":"172","author":"E Muchtar","year":"2015","unstructured":"Muchtar E, Gatt ME, Rouvio O et al (2015) Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. Br J Haematol 172:89\u201396","journal-title":"Br J Haematol"},{"key":"5811_CR14","doi-asserted-by":"publisher","unstructured":"Caro J, Al Hadidi S, Usmani S et al (2021) How to treat high-risk myeloma at diagnosis and relapse. https:\/\/doi.org\/10.1200\/EDBK_320105. ASCO Educational Book (asco.org\/edbook) \u2013 doi","DOI":"10.1200\/EDBK_320105"},{"key":"5811_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","volume":"138","author":"B Barlogie","year":"2007","unstructured":"Barlogie B, Anaissie E, van Rhee F et al (2007) Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 138:176\u2013185","journal-title":"Br J Haematol"},{"key":"5811_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00277-014-2023-2","volume":"93","author":"L Rasche","year":"2014","unstructured":"Rasche L, Strifler S, Duell J et al (2014) The lymphoma-like polychemotherapy regimen Dexa-BEAM in advanced and extramedullary multiple myeloma. Ann Hematol 93:1207\u20131214","journal-title":"Ann Hematol"},{"key":"5811_CR17","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.3324\/haematol.2014.115055","volume":"100","author":"I Isola","year":"2015","unstructured":"Isola I, Granell M, Mart\u00ec J et al (2015) PACE como tratamiento de rescate en pacientes con mieloma multiple reca\u00ecdo o refractario. Haematologica 100:S4 46# abstract CO-070","journal-title":"Haematologica"},{"issue":"2","key":"5811_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G et al (2010) Incidence presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21(2):325\u2013330","journal-title":"Ann Oncol"},{"issue":"2","key":"5811_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/10428190802657751","volume":"50","author":"P Wu","year":"2009","unstructured":"Wu P, Davies FE, Boyd K et al (2009) The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma 50(2):230\u2013235","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"5811_CR20","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.bbmt.2019.07.004","volume":"25","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Eikema DJ, Koster L et al (2019) Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the chronic malignancies working party of the European society for blood and marrow transplantation. Biol Blood Marrow Transpl 25(11):2134\u20132142","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"5811_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3109\/10428194.2011.606943","volume":"53","author":"H Landau","year":"2012","unstructured":"Landau H, Pandit-Taskar N, Hassoun H et al (2012) Bortezomib, liposomal doxorubicin, and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with International Staging System stage II or III, or extramedullary disease. Leuk Lymphoma 53(2):275\u2013281","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"5811_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2019.219139","volume":"105","author":"V Montefusco","year":"2020","unstructured":"Montefusco V, Gay F, Spada S et al (2020) Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica 105(1):193\u2013200","journal-title":"Haematologica"},{"key":"5811_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2312430","author":"G Mele","year":"2018","unstructured":"Mele G, Pastore D (2018) Efficacy of carfilzomib, lenalidomide and dexamethasone for Extramedullary Intracranial localization of multiple myeloma. Case Rep Hematol. https:\/\/doi.org\/10.1155\/2018\/2312430","journal-title":"Case Rep Hematol"},{"key":"5811_CR24","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ et al (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387:1551\u20131560","journal-title":"Lancet"},{"key":"5811_CR25","first-page":"5414","volume":"130","author":"J Minarik","year":"2017","unstructured":"Minarik J, Pour L, Maisnar V et al (2017) Single agent Daratumumab in advanced multiple myeloma: specific healthcare program in the Czech Republic. Blood 130:5414","journal-title":"Blood"},{"key":"5811_CR26","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00277-019-03655-5","volume":"98","author":"M Jullien","year":"2019","unstructured":"Jullien M, Trudel S, Tessoulin B et al (2019) Single agent daratumumab in very advanced relapsed and refractory multiple myeloma: a real-life single-center retrospective study. Ann Hematol 98:1435\u20131440","journal-title":"Ann Hematol"},{"issue":"S1","key":"5811_CR27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1182\/blood-2019-123143","volume":"134","author":"P Moreau","year":"2019","unstructured":"Moreau P, Zweegman S, Perrot A et al (2019) Evaluation of the prognostic value of positron emission tomography-computed tomography (PET-TC) at diagnosis and follow-up in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients treated in the phase 3 Cassiopeia Strudy: results of the Cassiopet companion study. Blood 134(S1):692","journal-title":"Blood"},{"key":"5811_CR28","doi-asserted-by":"crossref","unstructured":"Beksac M, Tuglular T, Gay F et al (2023) Efficacy of daratumumab plus bortezomib, cyclophosphamide and dexamethasone in patients with multiple myeloma presenting with extramedullary disease: a European myeloma network study (EMN19). EHA 2023, abstract n. P872","DOI":"10.1097\/01.HS9.0000970392.99459.3a"},{"issue":"178","key":"5811_CR29","first-page":"e328","volume":"2016","author":"S Kumar","year":"1958","unstructured":"Kumar S, Paiva B, Anderson KC et al (1958) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016(178):e328\u2013e346","journal-title":"Lancet Oncol"},{"key":"5811_CR30","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457\u2013481","DOI":"10.1080\/01621459.1958.10501452"},{"key":"5811_CR31","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K et al (2016) Daratumumab, bortezomib and dexamethasone for multiple myeloma. N Engl J Med 375:754\u2013766","journal-title":"N Engl J Med"},{"issue":"14","key":"5811_CR32","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H et al (2016) Daratumumab, Lenalidomide and Dexamethasone for multiple myeloma. N Engl J Med 375(14):1319\u20131331","journal-title":"N Engl J Med"},{"issue":"22","key":"5811_CR33","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T et al (2019) Daratumumab plus Lenalidomide and Dexamethasone for untreated myeloma. N Eng J Med 380(22):2104\u20132115","journal-title":"N Eng J Med"},{"issue":"6","key":"5811_CR34","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M et al (2018) Daratumumab plus Bortezomib, Melphalan and Prednisone for untreated myeloma. N Engl J Med 378(6):518\u2013528","journal-title":"N Engl J Med"},{"issue":"10192","key":"5811_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1)","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C et al (2019) Bortezomib, thalidomide and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomized, open-label, phase 3 study. Lancet 394(10192):29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1)","journal-title":"Lancet"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05811-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05811-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05811-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:06:14Z","timestamp":1735866374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05811-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5811"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05811-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"26 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No potential conflict of interest was reported by the author(s).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}